CA-SIGFOX/GOOGLE-CLOUD
11.2.2021 10:12:12 CET | Business Wire | Press release
Google Cloud and Sigfox today announced that the leading global 0G network and IoT platform services provider, has partnered with Google Cloud, to scale its cloud infrastructure and extend its IoT services portfolio. This partnership will enable Sigfox to rapidly accelerate its “Massive IoT” agenda – processing billions of messages each month from objects connected to the internet using data stored in the cloud.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210211005380/en/
Google Cloud was chosen as the backbone for Sigfox’s 0G network to bring better scale, increased reliability, and best-of-breed compliance and security to Sigfox’s platform. Google Cloud will also enable faster improvements to Sigfox’s connectivity, geolocation, and other value-added services towards ultra-low-cost and ultra-low-power IoT solutions.
Sigfox’s shift to the cloud will transform many of the applications across the range of industries in which it operates including supply chain and logistics, automotive, postal services and utilities. This includes the Sigfox auto parts solution which tracks components on their journeys between assembly plants and suppliers with sensor-equipped containers. Or Sigfox’s solutions for utility companies that digitize the data collection of gas consumption meters, retrofitted Network Controlling Units and smart features. Also, shipping companies fit trolley rollers or containers with Sigfox smart trackers to give exact information on location, movement and condition. All of them will be now cloud-enabled, helping provide a scalable and seamless way to manage exponential data growth.
"We chose Google Cloud because we share the same appetite for driving digital transformation through helpful, reliable and sustainable innovation. " said Franck Siegel, Deputy Chief Executive Officer, Sigfox . “With this partnership, Google Cloud technology will support us in becoming the global leader in ultra-low-cost, ultra-low-power asset visibility and tracking ”.
“Google Cloud is proud to support Sigfox and provide an IoT leader with more reliability and flexibility as the company takes the next steps of its development ,” said Samuel Bonamigo, VP Sales, EMEA South, Google Cloud . "Sigfox’s use of Google Cloud technology is the perfect illustration of how we’re helping innovative companies grow and thrive and better serve their customers .”
About Google Cloud
Google Cloud provides organizations with leading infrastructure, platform capabilities and industry solutions. We deliver enterprise-grade cloud solutions that leverage Google’s cutting-edge technology to help companies operate more efficiently and adapt to changing needs, giving customers a foundation for the future. Customers in more than 150 countries turn to Google Cloud as their trusted partner to solve their most critical business problems.
About Sigfox
Sigfox is the initiator of the 0G network and the world’s leading IoT (Internet of Things) service provider. It relies on a unique combination of ultra-low cost and ultra-low power technologies together with a global network to enable companies to gain visibility and track their assets worldwide for greater business results. With Sigfox, +17 million of devices send +60 million messages a day so that businesses can accelerate their digital transformation in key areas such as Asset Tracking and Supply Chain.
ISO 9001 certified and surrounded by a large ecosystem of partners and IoT key players, Sigfox has been founded in 2010 and is headquartered in France with offices in Madrid, Munich, Boston, Dallas, Dubai, Singapore, Sao Paulo and Tokyo.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005380/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom